Summary Thirty-eight patients with previously treated Hodgkin's disease were given high dose combination chemotherapy using melphalan and BCNU and autologous bone marrow transplantation. In 25 patients etoposide was added in conventional dosage. During the course of the study the dose of melphalan was increased from 80 to 140mg m-2 and the dose of BCNU from 300 to 600 mgm-2. The response rate was 76% with 53% complete remission. Forty-five per cent of the patients are free of disease at 4-20 months follow-up. There were eight (26%) treatment-related deaths due to lung damage (seven cases) and irreversible cardiac failure (one case). Fatal lung damage occurred only in patients receiving 600 mgm 2 of BCNU with high dose melphalan. The dose of BCNU given with high dose melphalan should not exceed 500mgm2. This treatment is effective against relapsed Hodgkin's disease but must be used cautiously. The best time for its use remains to be determined.
Despite improvements in radiotherapy and chemotherapy during the past 30 years, approximately 30% of patients with Hodgkin's disease (HD) will still die of their disease . Relapse after chemotherapy or failure to achieve remission with the first line treatment are ominous. Second line combination chemotherapy can produce good remission rates but cures are uncommon (Taylor et al., 1982; McElwain et al., 1985; Santoro et al., 1986; Hagemeister et al., 1987) . Radiotherapy can occasionally produce remissions in patients relapsing from chemotherapy (Roach et al., 1987; Fox et al., 1987) .
High dose chemotherapy with autologous bone marrow transplantation (ABMT) has been explored in the treatment of relapsed or resistant HD (Canellos, 1985; Canellos et al., 1987) . Recent reports indicate a high response rate between 52 and 95% with 18-70% relapse-free survival at 1-66 months (Ahmed et al., 1987; Carella et al., 1987; Jagannath et al., 1987; O'Reilly et al., 1987; Philip et al., 1986) . We initially explored high dose chemotherapy for HD with melphalan, 200 mgm2, followed by ABMT (Russell et al., 1988) . This produced a high response rate without treatmentrelated deaths and a 20% relapse-free survival at 5 years. It seemed probable that the results might be improved by a combination of active drugs given at high dose with ABMT. Among them, BCNU and etoposide are widely used. Thus, in the present study these drugs have been added to melphalan to make the combination known as MBE.
Patients and methods
Chemotherapy regimen For purposes of description, day 0 is the day when the autologous bone marrow is returned to the patient. MBE consisted of BCNU given intravenously on day -5 as a slow intravenous push over 10 min, melphalan given intravenously on day -4 with forced hydration as reported elsewhere (McElwain & Powles, 1983) and etoposide given intravenously on days -5, -4 and -3.
Dose escalation
The first two patients received BCNU 300mgm-2, etoposide 1,200mg m 2 and melphalan 80mg m-2 (one patient) or melphalan 100mgm-2 (one patient). Both developed severe Correspondence: T.J. McElwain. mucositis and the dose of etoposide was thereafter reduced to 300 mg m 2. The remaining 36 patients received melphalan 140 mgm-2 and the dose of BCNU was increased. One of these patients received BCNU 300 mgm-2; 11 received 400 mg m 2; three received 500 mg m-2 and 21 received 600 mg m -2. Twenty-three patients received etoposide 300mgm-2. Thirteen patients were not given any etoposide because their tumours had been previously shown to be refractory to this drug in this dose. Therefore 25 patients had a three drug combination with melphalan, BCNU and etoposide and 13 patients had a two drug combination with melphalan and BCNU only. Table II shows graphically the level of dosage and the drugs given in different groups of patients.
Patients
From November 1985 until November 1987, 38 consecutive patients with HD received MBE with ABMT. Twenty-three were male and 15 female. Ages were between 15 and 51 with a median of 28. Twenty-four patients had nodular sclerosing histology, six mixed cellularity, five lymphocyte depletion, one lymphocyte predominance and two were unclassified.
Before high dose treatment, patients were assessed by full blood count, erythrocyte sedimentation rate, urea, creatinine, liver function tests, glomerular filtration rate, bone marrow aspirate and trephine, chest X-ray and CT scan of chest and abdomen. Lung function and cardiac ejection fraction was not routinely measured.
Ann Arbor stages at initial diagnosis were IA for two patients, IIA for four, IIB for three, IIIA for two, IIIB for nine, IVA for five and IVB for 13. Eight patients had never achieved a complete remission and were considered to have primary drug resistant disease (Table I) . Ten patients received MBE as a consolidation therapy when in complete remission achieved only after multiple previous combination drug treatments (Table I) . The 20 remaining patients had relapsed from previous complete remissions. None of the prior complete remissions had lasted longer than 2 years. Sixteen of them had received drug combinations for their relapses but failed to enter complete remission before receiving MBE. Four had received such treatments but failed to respond (Table I) .
All patients referred to the Academic Medical Unit with relapsed or resistant HD were considered for this treatment. However, patients were excluded if they were unfit (WHO performance status <2; renal, hepatic or marrow failure) age >60 years or if their disease was very advanced and had been completely refractory to more than two combinations C) The Macmillan Press Ltd., 1989 Br. J. Cancer (1989 Patients were nursed in side rooms of general medical wards without special isolation procedures. They received oral antifungal prophylaxis with nystatin suspension and amphotericin lozenges. Toxicity was evaluated daily and assessed on the WHO scale (WHO, 1979) . A triple antibiotic combination with gentamycin 80 mg 8-hourly, piperacillin 4 g 6-hourly and flucloxacillin 500mg 6-hourly was started on day 1 and continued until the total white cell count recovered to 1 x 109 1-1 with at least 40% neutrophils. Appropriate changes in antibiotic treatment were made according to the clinical course. Antiviral chemotherapy prophylaxis was not routinely used.
Definition of response
Complete remission was defined as the disappearance of all abnormalities related to Hodgkin's disease and partial remission as 50% reduction in measurable tumour volume with associated symptomatic improvement. Early death was defined as any death occurring within 3 months after treatment regarded as being treatment related. Late toxic death is any treatment-related death occurring after 3 months. Patients who died early were not scored as responders even if tumour regression had occurred. Response rates were calculated as a proportion of all patients. An autopsy was performed in all but one patient who suffered toxic death.
Results
Therapeutic effect (responses assessed at 3 months) Among 28 patients who had measurable disease there were 13 complete remissions (CR=46%), nine partial remissions (PR=32%) and two did not respond (NR=7%). Four died early within 3 months (ED= 14%). Among the 10 patients in CR when treated, seven (70%) remained in CR at 3 months, two had ED (20%) and one progressed within 3 months. At the 3 months follow-up point, the overall outcome was 20 CR, 9 PR, 2 NR, 1 PD and 6 ED (Tables I and III) .
One patient (patient 7, Table I ) entered PR after MBE and is reported as such in Table I , Figure 2 and Figure 3 .
She received mantle irradiation to her residual disease (mediastinum and neck) which resulted in a CR which continues at 14 months.
Forty-five per cent of the patients assessable for response at 3 months are alive and in complete remission with a follow-up from 4 to 20 months (median 12 months). The overall cumulative probability of survival is 31% at 2 years (Figure 1) . However, the actuarial probability of remaining in remission for the 20 patients in CR at 3 months is 86% at 2 years. It is only 19% at 1 year for nine patients achieving a PR (Figure 2 ). The probability of disease free survival for patients in CR after MBE is 70% at 2 years as a consequence of late toxic deaths (Figure 3 ). (53) 9 (24) 3 (8) ) and 9 patients in PR (--- 
Discussion
This analysis allows us to draw some conclusions about the use of melphalan and BCNU in high dose in combination for Hodgkin's disease and in particular to highlight our substantial concern about their toxicity to the lungs. BCNU in high dose as a single agent is toxic to the lung but such toxicity is rare with doses below 800mg m-2 (Perren et al., 1987) . Melphalan alone causes transient, clinically insignificant lung toxicity (Allen et al., 1986) . High dose melphalan, 200mgm 2, did not produce significant lung toxicity during a prior study in a comparable group of patients (Russell et al., 1988) . With combination of doses of melphalan 140mgm 2 and BCNU 600mgm-2 we have seen a high rate of toxic deaths due to lung damage. This must represent an additive toxic effect and this incidence of severe toxicity precludes their usage together at these doses in these patients. The use of another alkylating agent, cyclophosphamide, given at high dose in combination with high dose BCNU and etoposide was not reported to cause such a high lung toxicity (Ahmed et al., 1987; Carella et al., 1987; Jagannath et al., 1987; O'Reilly et al., 1987; Philip et al., 1986) . In combination with high dose melphalan, 140mgm2, we now limit the dose of BCNU to a maximum of 500mgm2.
Nevertheless, there is no doubt that this approach leads to high remission rate for patients with very aggressive HD. In our study the overall response rate to MBE was 76%, with 53% of patients in CR at 3 months. The actuarial risk of relapse before 2 years is only 14% but median follow-up is only 1 year. The overall survival falls to 31% at 2 years as a consequence of the toxic deaths. Since the goal of these treatments is long-term disease-free survival, follow-up to 5 years is required to allow firm conclusions. The precise place of intensive chemotherapy for HD remains to be determined. To date all studies including this one have suffered from case selection and lack of a control arm. Studies are now required in relapsed or resistant patients to randomise conventional treatment against intensive regimens. Intensive treatments are likely to be associated with far less toxicity than hitherto, both because of what has been learned from studies of the type reported here and the relative lack of prior tissue damage in patients who receive high dose treatment earlier.
